And the most recent article came out of JAMA in 2024, and they found that for every 1 g increase in urinary sodium, you ...
FibroBiologics is pursuing a development program for CYPS317 with the goal of advancing first-in-human clinical trials following FDA review of the IND filing. The IND submission includes comprehensive ...
Oral roflumilast showed potential as a nonbiologic systemic therapy for moderate to severe psoriasis, offering an alternative ...
In the second half of his Maui Derm recap, George Martin, MD, founder and program director of the meeting, highlights new ...
Researchers have uncovered a previously unrecognized role for immune cell surface sugars in driving inflammation in psoriasis. Scientists have refined how they understand the role of sugars called ...
Takeda Pharmaceutical Co. announced that its oral psoriasis drug zasocitinib proved safe and effective in late-stage trials, ...
The clinical-stage biotechnology company is seeking regulatory clearance to begin clinical trials of CYPS317, an allogeneic ...
Takeda reports positive Phase 3 data for psoriasis drug zasocitinib, beating placebo and Otezla, with rapid PASI responses ...
Complete clearance lasts for a very long time due to knockout of resident memory T cells within the skin,’ said the study’s ...
Compared to Sotyktu (deucravacitinib), which was approved by the FDA for plaque psoriasis in 2022 and brought in sales of ...
Japan's Takeda Pharmaceutical said on Thursday its experimental pill for a type of skin disease, developed using artificial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback